Plus Therapeutics · US72941H4002 · PSTV | XNAS | Prime AI Terminal

CUSIP

72941H400

SEDOL

N/A

CIK

0001095981

www.plustherapeutics.com

LEI:

Plus Therapeutics, Inc.

BASIC = Free ADVANCED = User Account BUSINESS = Subscription PRIME = Subscription

ENTERPRISE = upon request

PROFILER

BASIC

ADVANCED

BUSINESS

PRIME

AI Insights

Plus Therapeutics

Click to initiate

ENTERPRISE

Securities Trading Warrants

GlobeNewswire is an important news source that provides investors with company-related information. In particular, it deals with events that may be relevant to the listing of companies or tradable financial instruments. You can access the complete overview of all reports via this link.

Thu, 14.11.2024

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Research & Analysis

Wed, 14.08.2024

Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Research & Analysis

Fri, 17.05.2024

Plus Therapeutics Announces New Employment Inducement Grants

Research & Analysis

Wed, 15.05.2024

Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Research & Analysis

Thu, 09.05.2024

Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial

Research & Analysis

Wed, 08.05.2024

Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial

Research & Analysis

We are different

OPEN FINANCIAL

DATA & KNOWLEDGE HUB

We make the difference

Information on product placements

SMART * AD

P R O D U C T S U G G E S T I O N S

Subject *

i.e Feature x is not working

Issue happened on *

This page

Other page

Page URL

Paste the page URL here

Bug Detail *

Please give us more detailed explanation of the issue

Steps to reproduce *

Specify the steps you've done before the issue happen

Actual Result *

What's the result of the issue?

Expected Result *

What do you expect to see?

Attachment

(Optional) You can send us a screenshot, word document, or a PDF explaining the issue

You have pressed the "". We would like to inform you that you are now leaving the information service of the portal site ayondo.com. You will be redirected to . After confirming the "Continue" button, you confirm that you have been informed of this. You also confirm that you are carrying out this process of your own free will and that it is not the result of any promotional activity or other influence. Continue to .

I would like to remain anonymous.

Subject *

e.g. New calculation method for Risk-of-Ruin-Calculator

View/Tool *

This view/tool

Another page/tool

Description of the proposed change/feedback *

The more comprehensible the description, the faster a feasibility check can be carried out.

General feedback on the view/tool/component/content *

Use this feedback text field for general or supplementary information

Would you use the tool and recommend it if necessary? *

Your opinion is valuable. Feel free to share it with us.

Plus Therapeutics, Inc.

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Plus Therapeutics Announces New Employment Inducement Grants

Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial

Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial

Newsletter